Earnings per share (Tables)

3 Months Ended

Apr. 02, 2022

Earnings Per Share [Abstract]

Schedule of Earnings Per Share

The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the period following the Transactions (amounts in thousands, except share and per share data):

	Three Months Ended April 2, 2022		February 16, 2021 through April 3, 2021
Numerator:
Net loss	$	(14,806)	(1,449)
Net loss attributable to noncontrolling interests	3,529		408
Net loss attributable to Bioventus Inc. Class A common stockholders	$	(11,277)	$	(1,041)
Denominator:
Weighted-average shares of Class A common stock outstanding - basic and diluted	60,484,969		41,797,882
Net loss per share of Class A common stock, basic and diluted	$	(0.19)	$	(0.02)

Schedule of Antidilutive Securities

The following number of weighted-average potentially dilutive shares as of April 2, 2022 and April 3, 2021 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:

	Three Months Ended April 2, 2022	February 16, 2021 through April 3, 2021
LLC Interests held by Continuing LLC Owner(a)	15,786,737	15,786,737
Stock options	8,757,706	4,564,091
RSUs	462,404	382,711
Unvested shares of Class A common stock	—	39,129
Total	25,006,847	20,772,668

(a)Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by Continuing LLC Owner.